Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03115853 · ClinicalTrials.gov registry record · Phase 4
The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function
A Phase 4 study of High Blood Pressure, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT03115853: Completed Phase 4 study of High Blood Pressure, sponsored by Vanderbilt University Medical Center.
NCT03115853 is a Phase 4 study of High Blood Pressure that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 31 participants, below the 503-participant average among 23 other High Blood Pressure trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03115853, a Phase 4 study of High Blood Pressure, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amount of a substance known as Plasminogen Activator Inhibitor or PAI-1. This study will measure how aliskiren changes the amount of PAI-1 in the blood depending on the time of dosing. The purpose of this study is to find out if it is better to take aliskiren in the morning or at night.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aliskiren 150 mg
- DRUG HCTZ
- DRUG Aliskiren 300 mg
Study Locations (1)
Tennessee
- VUMC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
What the finished NCT03115853 record still lists
NCT03115853 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 503-participant average among 23 other High Blood Pressure trials with a reported enrollment target (94% lower).
The record links to 1 condition, with High Blood Pressure appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03115853 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03115853 about?
NCT03115853 is a clinical study titled "The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function". Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amoun...
What is the current status of trial NCT03115853?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2009-06. Estimated completion is 2012-01.
What conditions does trial NCT03115853 study?
This clinical trial studies the following conditions: High Blood Pressure.
What interventions are being tested in trial NCT03115853?
The interventions under investigation include: Placebo (DRUG), Aliskiren 150 mg (DRUG), HCTZ (DRUG), Aliskiren 300 mg (DRUG).
Who is sponsoring clinical trial NCT03115853?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03115853 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03115853's enrollment target sits among peer trials
31 19th of 23 higher than 5 of 23 other High Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Addressing Hypertension Care in Africa Program
RECRUITING · NA
-
Blood Pressure Care for Advancing Real-World Evidence (BPCARE)
RECRUITING · NA
-
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
RECRUITING · Phase 3
-
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
RECRUITING · NA
-
Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region Project 1 - Epidemiology (ACHIEVE P1-EPI)
RECRUITING · NA
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia